Skip to content
DataLookout
Menu

NCT02612454

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 15 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words Show 4 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Oct 7, 2026 to Oct 9, 2026
    • Secondary endpoints: details revised at 8 of 17 entries
    • Publications: details revised at 8 of 8 entries
  2. Minor Primary and study completion dates: Aug 19, 2026 to Oct 7, 2026v15
  3. Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: estimated 800 to confirmed 880
    • Primary and study completion dates: Nov 3, 2026 to Aug 19, 2026
    v13
  4. Notable Eligibility criteria expanded, about 113 words
    • Primary endpoints: 2 to 6
    • Primary and study completion dates: Dec 17, 2026 to Nov 3, 2026
    • Secondary endpoints: 16 to 17
    v12
  5. Minor Study sites: 102 to 84v11
Show 9 earlier versionsHide 9 earlier versions
  1. Notable Primary and study completion dates: Nov 16, 2023 to Dec 17, 2026v10 Show 4 more changesShow less
    • Eligibility criteria revised
    • Enrollment target: 765 to 800
    • Study sites: 97 to 102
    • Study arms: 1 to 4
  2. Minor Study sites: 95 to 97v9
  3. Minor Study sites: 92 to 95
    • Primary and study completion dates: Jan 25, 2024 to Nov 16, 2023
    v8
  4. Minor Study sites: 90 to 92v7
  5. Minor Study sites: 78 to 90
    • Primary and study completion dates: Oct 16, 2023 to Jan 25, 2024
    • Start date: Oct 22, 2015 to Oct 15, 2015
    v6
  6. Minor Study sites: 72 to 78v5
  7. Notable Eligibility criteria expanded, about 41 wordsv4 Show 5 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 25 to 72
    • Secondary endpoints revised (16)
    • Study arms: 2 to 1
    • Study title shortened, about 1 word
  8. Notable Enrollment target: 69 to 765v3 Show 6 more changesShow less
    • Primary and study completion dates: Oct 2018 to Oct 16, 2023
    • Eligibility criteria shortened, about 78 words
    • Primary endpoints: 1 to 2
    • Start date: Oct 2015 to Oct 22, 2015
    • Secondary endpoints: 4 to 16
    • Study title revised
  9. Minor Enrollment target: 80 to 69
    • Primary and study completion dates: Jul 2018 to Oct 2018
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visit
Timeframe: Baseline up to week 272
Number of participants with at least one TEAE per participant year from baseline through the last study visit
Timeframe: Baseline up to week 272
OPTIONAL SUB-STUDY: Pharmacokinetic (PK) of dupilumab: Peak concentration (Cmax)
Timeframe: Up to week 16
OPTIONAL SUB-STUDY: PK of dupilumab: Trough concentration (Ctrough)
Timeframe: Up to week 16
OPTIONAL SUB-STUDY: Incidence of TEAEs during the 12-week PFP treatment period and during entire sub-study
Timeframe: Up to week 16
OPTIONAL SUB-STUDY: Incidence of SAEs during the 12-week PFP treatment period and during entire sub-study
Timeframe: Up to week 16

Secondary (17)

Number of treatment-emergent serious adverse events (SAEs) from baseline through the last study visit
Incidence of TEAEs of special interest from baseline through the last study visit
Proportion of participants with an Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear) at all in-clinic visits post-baseline
Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% reduction in EASI from baseline of parent study) response at all in-clinic visits post-baseline
Change from baseline in EASI score at all in-clinic visits post-baseline
Show 12 moreShow less
Percent change from baseline in EASI at all in-clinic visits post-baseline
Change from baseline in Body Surface Area (BSA) affected by AD (BSA) at all in-clinic visits post-baseline
Percent change from baseline in SCORing Atopic Dermatitis (SCORAD) at all in-clinic visits post-baseline
Change from baseline in Children's Dermatology Life Quality Index (CDLQI) for participants ≥4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed
Change from baseline in Infants' Dermatology Quality of Life Index (IDQOL) for participants <4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed
Proportion of responders (defined as participants with IGA 0 or 1) who maintain IGA 0 or 1 during at least 75% of the subsequent* visits during the treatment period
For responders (defined as participants with IGA 0 or 1), median percentage of subsequent* visits during the treatment period, at which IGA 0 or 1 is maintained
Number of AD flares during the study
Annualize event rate of AD flares during the study
Proportion of participants with at least one flare during the study
Proportion of well-controlled weeks
OPTIONAL SUB-STUDY: Incidence and titer of treatment-emergent anti-drug antibodies (ADA) (PFP Sub-Study)

Arms and interventions

Body weight ≥60 kgExperimental

Administered every two weeks (Q2W)

Body weight 30 kg to <60 kgExperimental

Administered Q2W

Body weight 15 kg to <30 kgExperimental

Administered every 4 weeks (Q4W)

Body weight 5 kg to <15 kgExperimental

Administered Q4W

Drugs: Dupilumab

Sites

84 sites in 7 countries

United States 40, Poland 17, Canada 9, Germany 8, Hungary 4, Czechia 3, United Kingdom 3